BeStock  
Stocks › Biotechnology › XENE

Xenon Pharmaceuticals XENE

US equityMarket cap rank #2284Biotechnology
$37.04 −$0.52 (-1.38%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $37.04 0.00%
Open$37.22
Prev close$37.56
Day range$36.81 – $37.97
Volume1.09M
Market cap$3.64B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$120.07M-24.6% YoY
Net profit-$110.44M-21.5% YoY
Diluted EPS-$1.11+3.5% YoY
Free cash flow-$90.61M-25.8% YoY
Operating cash flow-$90.33M

Revenue, last 8 quarters

$0.0Dec '24$7.5MMar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-65.7MDec '24$-65.0MMar '25$-84.7MJun '25$-90.9MSep '25$-105.3MDec '25$-102.3MMar '26$-110.7MJun '26$-110.4MSep '26

Diluted EPS by quarter

-0.84Dec '24-0.83Mar '25-1.07Jun '25-1.15Sep '25-1.31Dec '25-1.17Mar '26-1.11Jun '26-1.11Sep '26

Free cash flow by quarter

$-55.2MDec '24$-61.7MMar '25$-64.4MJun '25$-72.0MSep '25$-81.8MDec '25$-89.0MMar '26$-95.7MJun '26$-90.6MSep '26

Annual revenue

$32.2MFY20$18.4MFY21$9.4MFY22$0.0FY23$0.0FY24$7.5MFY25

Profitability & balance sheet

Return on equity-50.3%
Return on assets-47.4%
Return on invested capital-54.0%
Current ratio21.19
Liabilities / assets4.5%
Cash & investments$950.80M
Total debt$4.86M
Net cash (debt)$945.94M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $0.00 $0.00 $0.00 $7.50M $0.00
Total Operating Revenue $0.00 $0.00 $0.00 $7.50M $0.00
Operating Expense $120.07M $123.16M $112.33M $380.57M $109.77M
Selling and Admin Expenses $24.42M $23.93M $23.82M $79.63M $22.07M
-General & Admin Expense $24.42M $23.93M $23.82M $79.63M $22.07M
Research & Development $95.65M $99.22M $88.51M $300.94M $87.70M
Operating Profit -$120.07M -$123.16M -$112.33M -$373.07M -$109.77M
Net Non-Operating Interest Income (Expense) $11.62M $12.15M $6.91M $26.83M $5.34M
Non-Operating Interest Income $11.62M $12.15M $6.91M $26.83M $5.34M
Other Income (Expense) -$142,000.00 -$311,000.00 $548,000.00 $1.35M -$296,000.00
Gain on Sale of Security -$142,000.00 -$311,000.00 $548,000.00 $1.35M -$296,000.00
Pretax Profit -$108.59M -$111.32M -$104.87M -$344.89M -$104.72M
Tax $1.84M -$585,000.00 -$2.57M $1.02M $538,000.00
Net Profit -$110.44M -$110.74M -$102.30M -$345.91M -$105.26M
Profit from Continuing Operations -$110.44M -$110.74M -$102.30M -$345.91M -$105.26M
Net Income to Parent Company -$110.44M -$110.74M -$102.30M -$345.91M -$105.26M
Net Income to Common Stockholders -$110.44M -$110.74M -$102.30M -$345.91M -$105.26M
Basic EPS -$1.11 -$1.11 -$1.17 -$4.36 -$1.31
Diluted EPS -$1.11 -$1.11 -$1.17 -$4.36 -$1.31

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.20B $1.30B $1.39B $633.16M $633.16M
Total Current Assets $960.07M $945.87M $1.11B $560.65M $560.65M
Cash and Cash Equivalents & Short-Term Investments $950.80M $930.69M $1.09B $548.89M $548.89M
-Cash and Cash Equivalents $82.56M $119.53M $545.87M $199.16M $199.16M
-Short Term Investments $868.24M $811.16M $548.88M $349.72M $349.72M
Receivables $1.17M $1.63M $1.17M $1.37M $1.37M
-Accounts Receivable $1.17M $1.63M $1.17M $1.37M $1.37M
Other Current Assets $8.10M $13.55M $10.72M $10.39M $10.39M
Total Non-Current Assets $239.81M $349.90M $280.18M $72.51M $72.51M
Net PPE $12.52M $13.16M $14.58M $15.35M $15.35M
-Gross PPE $12.52M $13.16M $14.58M $30.80M $30.80M
Investments and Advances $202.68M $314.41M $244.87M $37.15M $37.15M
-Available for Sale Securities $202.68M $314.41M $244.87M $37.15M $37.15M
Non-Current Prepaid Assets $9.16M $7.97M $8.31M $7.15M $7.15M
Non-Current Deferred Assets $15.46M $14.36M $12.42M $12.86M $12.86M
Total Liabilities $53.49M $53.38M $48.99M $51.40M $51.40M
Total Current Liabilities $45.30M $45.01M $39.82M $41.79M $41.79M
Payables $2.03M $3.42M $6.02M $4.20M $4.20M
-Accounts Payable $1.93M $2.48M $5.75M $3.89M $3.89M
-Total Tax Payable $106,000.00 $935,000.00 $269,000.00 $313,000.00 $313,000.00
Current Accrued Expenses $27.52M $29.23M $24.61M $21.60M $21.60M
Short-Term Debt and Capital Lease Obligation $1.15M $1.34M $1.56M $1.53M $1.53M
-Current Capital Lease Obligation $1.15M $1.34M $1.56M $1.53M $1.53M
Total Non-Current Liabilities $8.19M $8.37M $9.18M $9.61M $9.61M
Long Term Debt and Capital Lease Obligation $4.86M $5.08M $5.93M $6.41M $6.41M
-Long Term Capital Lease Obligation $4.86M $5.08M $5.93M $6.41M $6.41M
Other Non-Current Liabilities $3.33M $3.29M $3.25M $3.20M $3.20M
Total Equity $1.15B $1.24B $1.34B $581.76M $581.76M
Stockholders' Equity $1.15B $1.24B $1.34B $581.76M $581.76M
Capital Stock $2.49B $2.43B $2.42B $1.60B $1.60B
-Common Stock $2.49B $2.43B $2.42B $1.60B $1.60B
Additional Paid-In Capital $227.29M $276.85M $264.88M $228.23M $228.23M
Retained Earnings -$1.57B -$1.46B -$1.35B -$1.25B -$1.25B
Gains/Losses Not Affecting Retained Earnings -$5.05M -$2.66M -$1.21M $335,000.00 $335,000.00
-Accumulated Depreciation – – – -$15.45M -$15.45M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$90.33M -$95.39M -$88.90M -$279.12M -$81.48M
Net cash flow from continuing operations -$90.33M -$95.39M -$88.90M -$279.12M -$81.48M
Net Income from Continuing Operations -$110.44M -$110.74M -$102.30M -$345.91M -$105.26M
Gain/Loss from Continuing Operations $36,000.00 -$725,000.00 -$604,000.00 $698,000.00 $179,000.00
Depreciation & Depletion & Amortization $562,000.00 $558,000.00 $587,000.00 $2.54M $611,000.00
Deferred Tax -$1.10M -$1.94M $447,000.00 -$3.20M -$1.11M
Other Non-Cash Items $330,000.00 $1.20M -$539,000.00 $1.31M $334,000.00
Change in Working Capital $4.95M $2.43M -$3.38M $4.36M $8.97M
-Change in Receivables $462,000.00 -$467,000.00 $205,000.00 $104,000.00 -$559,000.00
-Change in Prepaid Assets $4.31M -$2.50M -$1.48M -$3.16M $6.63M
-Change in Payables and Accrued Expense $499,000.00 $5.72M -$1.80M $5.51M $3.19M
-Change in Other Current Liabilities -$459,000.00 -$317,000.00 -$302,000.00 $1.90M $2.86M
Net cash flow from investing $53.19M -$331.24M -$407.28M $218.00M $62.70M
Net Cash Flow from Continuing Investing Activities $53.19M -$331.24M -$407.28M $218.00M $62.70M
Net PPE Purchase and Sale -$284,000.00 -$275,000.00 -$133,000.00 -$799,000.00 -$318,000.00
Net Investment Purchase and Sale $53.48M -$330.96M -$407.15M $218.80M $63.02M
Financing Cash Flow $228,000.00 $26,000.00 $843.01M $117.11M $113.54M
Net Cash Flow from Continuing Financing Activities $228,000.00 $26,000.00 $843.01M $117.11M $113.54M
Net Common Stock Issuance $0.00 $0.00 $837.53M $112.15M $112.15M
Proceeds from Stock Option Exercised $228,000.00 $26,000.00 $5.49M $4.96M $1.39M
Ending Cash Balance $82.56M $119.53M $545.87M $199.16M $199.16M
Net Change in Cash -$36.91M -$426.60M $346.83M $55.99M $94.75M
Beginning Cash Balance $119.53M $545.87M $199.16M $142.71M $104.51M
Effect of Exchange Rate Changes -$57,000.00 $262,000.00 -$130,000.00 $458,000.00 -$104,000.00
Free Cash Flow -$90.61M -$95.67M -$89.03M -$279.92M -$81.80M

Discussion

No comments yet — be the first to weigh in on XENE.

Sign in to join the discussion.

Scroll to Top